olaratumab + vincristine + irinotecan

**Olaratumab + vincristine + irinotecan** is a three-drug combination regimen, not currently known under a unique brand or code name, designed for investigational use in oncology. **Olaratumab** is a recombinant human IgG1 monoclonal antibody targeting platelet-derived growth factor receptor alpha (PDGFRα), inhibiting its signaling and thereby preventing tumor cell proliferation and survival. **Vincristine** is a vinca alkaloid that binds tubulin, inhibiting microtubule formation and preventing mitosis in dividing cells. **Irinotecan** is a topoisomerase I inhibitor that stabilizes the topoisomerase I-DNA complex, thus introducing DNA breaks and inducing cell death. Each drug acts via a distinct mechanism, targeting overlapping yet complementary aspects of tumor biology. This combination is investigational; it is not an approved therapy and specific efficacy, safety data, and regulatory status for this exact regimen are not currently available. However, all three agents are established anticancer drugs used separately or in other combinations, mostly in sarcomas and other solid tumors[1][5].